Dyadic International (NasdaqCM:DYAI) Conference Transcript

Summary of Dyadic International Conference Call - December 09, 2025 Company Overview - Company: Dyadic International (NasdaqCM:DYAI) - Industry: Biomanufacturing, Life Sciences, Food Nutrition, Bio-Industrial Markets - Focus: Scalable, animal-free recombinant protein solutions Key Points and Arguments 1. Commercial Inflection Point: Dyadic is at a significant commercial inflection point with multiple products entering the market and active revenue engines [2][4][30] 2. Transition from R&D to Commercialization: The company has shifted focus from R&D and grant-based revenues to commercial applications, particularly in non-therapeutic areas that do not require FDA review [3][5][30] 3. Product Launch Timeline: Dyadic expects multiple product launches starting in 2025 and continuing through 2027, with a focus on life sciences, food nutrition, and bio-industrial segments [4][10][32] 4. Platform Technologies: The company utilizes two main platforms, C1 and Dapibus, designed for speed, productivity, scale, and low cost, to produce recombinant animal-free protein solutions [7][9][30] 5. Market Segments: - Life Sciences: Focus on cell culture media, cell and gene therapy, and high-value proteins like human transferrin and albumin [11][15][19] - Food Nutrition: Targeting the alternative protein market, particularly non-animal dairy and functional food proteins, with a market size estimated at $50-$70 billion [12][22] - Bio-Industrial: Re-entering the market through partnerships, focusing on cellulosic enzymes with a market size of approximately $6 billion [13][14][23] 6. Revenue Generation Strategy: Dyadic employs a three-pillar strategy: buy, brand, and build, allowing for direct sales, licensing, and partnerships to monetize its technology [9][10][19] 7. Partnerships: Collaborations with companies like Proliant Health and Fermbox Bio are expected to drive revenue growth and product launches [16][23][29] 8. Regulatory Advantages: The focus on non-therapeutic products allows for faster market entry, with timelines of 12-18 months from proof of concept to revenue [5][18][31] 9. Financial Projections: The company anticipates meaningful revenue growth starting in early 2026, with a revenue run rate of approximately $12 million needed to reach cash flow positive status [33][37] Additional Important Information - Innovation and Technology: Dyadic has access to CRISPR technology, enhancing its ability to optimize production strains [4][30] - Market Trends: The shift towards sustainable and predictable proteins is driving demand for Dyadic's products, particularly in the context of growing consumer preference for non-animal sources [3][12] - Future Outlook: The company is positioned for significant growth with a layered revenue approach, leveraging existing partnerships and expanding its product portfolio [26][27][32] This summary encapsulates the key insights from the Dyadic International conference call, highlighting the company's strategic direction, market opportunities, and financial outlook.